Medtronic DTM SCS Endurance Therapy Data Shows Meaningful Pain Relief

Medtronic released three-month results at this year’s North American Neuromodulation Society (NANS) Annual Meeting from a multi-center study¹ demonstrating “meaningful” pain relief using its Differential Target Multiplexed (DTM) spinal cord stimulation (SCS) endurance therapy. DTM SCS endurance therapy is a modified, lower energy version of Medtronic’s DTM SCS therapy for chronic overall, back, or leg pain.
 
After three months of treatment patients reported pain relief measuring 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale (VAS).2 An average 4.3 cm reduction was reported for back pain, and average 5 cm decrease for leg pain. VAS is a widely used, accepted pain intensity measurement capturing patient-reported pain levels on a scale of one to ten.
 
69 percent of patients also improved to a less disabled category per the Oswestry Disability Index. 63 percent have minimal to moderate disability at three months compared to 16 percent at baseline.
 
“These 3-month results are highly encouraging, as they demonstrate that the DTM SCS endurance therapy may be able to provide effective pain relief while dosing at lower energy than other SCS waveforms,” Dr. Kasra Amirdelfan, director of Clinical Research at IPM Medical Group and principal investigator on the DTM-LE Trial told the press. “This may improve device longevity and offers validation of therapy for the patients who would need it.”
 
“Every patient with chronic pain has their own unique needs, and Medtronic is committed to offering solutions that personalize care for our patients,” said Charlie Covert, vice president and general manager of Pain Therapies at Medtronic. “For many, especially those who need or prefer a recharge-free SCS solution, our new DTM SCS endurance therapy offers meaningful clinical benefits by reducing pain, improving quality of life, and offering meaningful device longevity.”
 
Patients in this study will have further follow-up assessments at six and twelve months.
 
References
¹ Using the Intellis with AdaptiveStim neuromodulation system
² Peacock, Provenzano, Fishman, et al. A Prospective Multi-Center Study of a Differential Target Multiplexed Stimulation Derivative in Therapy-Naive Patients: Primary Endpoint and 3-Month Outcomes. Poster presented at: North American Neuromodulation Society (NANS) Annual Meeting; Jan. 13-15, 2022; Orlando, FL.